Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Retinal Pharmaceuticals Market – Detailed Analysis of Current Industry Figures with Forecasts Growth By 2024

The Global Retinal Pharmaceuticals Market 2019-2024 Renders deep perception of the Market Segment by Regions, market status of the Retinal Pharmaceuticals on a global level that primarily aims the core...

VRX.TO : 30.80 (-3.33%)
BAYRY : 17.1000 (+1.18%)
SNPHF : 15.0163 (+1.46%)
NVS : 80.60 (+3.57%)
SHPG : 179.20 (+4.10%)
REGN : 349.99 (+2.80%)
Global Ophthalmology Therapeutics Market 2019-2023 - Key Players are Allergan, F. Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, and Santen Pharmaceutical - ResearchAndMarkets.com

The "Global Ophthalmology Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

REGN : 349.99 (+2.80%)
Shares of REGN Down 17.2% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Regeneron Pharm (NASDAQ:REGN) on March 8th, 2019 at $403.55. In approximately 2 month, Regeneron Pharm has returned 17.23% as of today's recent price of $334.03.

REGN : 349.99 (+2.80%)
SmarTrend Watching for Potential Rebound in Shares of Regeneron Pharm After 4.68% Loss

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $350.50 to a high of $363.09. Yesterday, the shares fell 4.7%, which took the trading range below the 3-day low of...

REGN : 349.99 (+2.80%)
Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran

Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.

MDCO : 29.80 (+1.15%)
ALNY : 87.88 (+2.94%)
NVS : 80.60 (+3.57%)
REGN : 349.99 (+2.80%)
Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA

The FDA accepts Novartis' (NVS) BLA seeking approval for brolucizumab for the treatment of wet AMD.

NVS : 80.60 (+3.57%)
RHHBY : 32.4500 (-0.98%)
REGN : 349.99 (+2.80%)
GSK : 40.22 (+0.73%)
Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran

Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.

MDCO : 29.80 (+1.15%)
ALNY : 87.88 (+2.94%)
NVS : 80.60 (+3.57%)
REGN : 349.99 (+2.80%)
Regeneron Pharm Falls 1.94% on Heavy Volume: Watch For Potential Rebound

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $385.86 to a high of $389.43. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of...

REGN : 349.99 (+2.80%)
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

We take a look at companies, which have been developing treatments for various diseases using RNAi technology.

ABUS : 2.58 (-5.84%)
DRNA : 13.56 (+0.22%)
ARWR : 19.05 (+0.58%)
ALNY : 87.88 (+2.94%)
REGN : 349.99 (+2.80%)
MRNA : 25.74 (-0.08%)
Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More

Key highlights of the past week are new drug approvals, collaborations and pipeline updates.

CELG : 93.92 (+0.88%)
ALNY : 87.88 (+2.94%)
GILD : 64.14 (+2.13%)
REGN : 349.99 (+2.80%)
AMGN : 180.48 (+1.22%)
UTHR : 102.04 (-1.41%)
Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics

Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).

BAYRY : 17.1000 (+1.18%)
ALNY : 87.88 (+2.94%)
REGN : 349.99 (+2.80%)
SNY : 41.21 (-0.65%)
Regeneron to Report First Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2019

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2019 financial and operating results on Tuesday, May 7, 2019, before the U.S. financial markets open....

REGN : 349.99 (+2.80%)
Watch for Regeneron Pharm to Potentially Rebound After Falling 2.83% Yesterday

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $396.74 to a high of $400.89. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of...

REGN : 349.99 (+2.80%)
Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

--a^' Regeneron to Invest $800 million Through Upfront Cash and Equity Investment in Alnylam, with up to Additional $200 Million in Potential Near-Term Milestones -

ALNY : 87.88 (+2.94%)
REGN : 349.99 (+2.80%)
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

Companies to also jointly advance select number of preclinical disease programs with targets expressed in the liver and treatments for C5 complement-mediated diseases

ALNY : 87.88 (+2.94%)
REGN : 349.99 (+2.80%)
Cat Allergy Pipeline Review, H1 2019 Featuring ALK-Abello, Amgen, Biomay, & Regeneron Pharmaceuticals - ResearchAndMarkets.com

The "Cat Allergy - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

REGN : 349.99 (+2.80%)
Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up

Inovio's (INO) investigational HPV therapy, INO-3106, achieves the clinical efficacy for treating patients with recurrent respiratory papillomatosis, an HPV-associated disease. Shares up.

AZN : 39.06 (+0.88%)
INO : 3.84 (+1.05%)
RHHBY : 32.4500 (-0.98%)
REGN : 349.99 (+2.80%)
Allergan's AMD Drug Lowers Inflammation in Phase III Study

Allergan's (AGN) MAPLE study evaluating a 12-week dose of abicipar pegol demonstrates decreased intraocular inflammation in nAMD patients.

AGN : 141.49 (+1.31%)
NVS : 80.60 (+3.57%)
RHHBY : 32.4500 (-0.98%)
REGN : 349.99 (+2.80%)
SmarTrend Watching for Potential Pullback in Shares of Regeneron Pharm After 1.17% Gain

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $409.32 to a high of $414.84. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high...

REGN : 349.99 (+2.80%)
Inovio Closes Enrollment in Brain Cancer Study Before Time

Inovio (INO) concludes enrollment in the phase I/II study on INO-5401+INO-9012 combined with Regeneron/Sanofi's Libtayo for the newly-diagnosed subjects with glioblastoma prior to the scheduled date.

INO : 3.84 (+1.05%)
RHHBY : 32.4500 (-0.98%)
REGN : 349.99 (+2.80%)
SNY : 41.21 (-0.65%)

Van Meerten Stock Picks

Aaon - Pick of the Day
My Stock Pick of the Day is the HVAC company AAON (AAON).
AAON -0.48
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar